Symbols

ATAI

AtaiBeckley·NASDAQ

--(--)

ATAI Profile

Ataibeckley Inc.

A clinical-stage biopharmaceutical company that developing treatment for mental health disorders

Industry

Pharmaceutical

Established Date

09/10/2020

Listing Date

06/18/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.ataibeckley.com

Security Type

Common stock

Office address

250 West 34th Street, New York, NY 10119

Business

Introduction

AtaiBeckley Inc., was incorporated under the laws of the Netherlands on September 10, 2020. On January 11, 2021, it was renamed ATAI Life Sciences B.V. On November 5, 2025, it was renamed Atai Beckley N.V. On January 2, 2026, the company name was changed to AtaiBeckley Inc., and it was transformed into a company incorporated under the laws of the State of Delaware. The company is a clinical-stage biotechnology company focused on the development of new, psychedelic-based neuroplastic drugs for difficult-to-treat mental health disorders. Its R&D pipeline includes research projects for treatment-resistant depression and social anxiety disorder, as well as a drug discovery program for novel non-hallucinogenic compounds.